Ultragenyx Pharmaceutical (RARE) Long-Term Investments (2015 - 2026)

Ultragenyx Pharmaceutical (RARE) has 12 years of Long-Term Investments data on file, last reported at $121.0 million in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 76.48% year-over-year to $121.0 million in Q1 2026; TTM through Mar 2026 was $121.0 million, a 76.48% increase from a year earlier, with the FY2025 full-year figure at $57.0 million, down 57.78% from the prior year.
• Long-Term Investments for Q1 2026 stood at $121.0 million, up from $57.0 million in the prior quarter.
• Over the last five years, Long-Term Investments for RARE reached as high as $215.5 million in Q1 2022 and fell as low as $22.1 million in Q3 2025.
• Historically, Long-Term Investments has averaged $117.3 million across 5 years, with a median of $110.7 million in 2024.
• Across the five-year window, Long-Term Investments jumped 164.05% in 2022 and slumped 89.13% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $149.0 million in 2022, then surged by 34.19% to $199.9 million in 2023, then tumbled by 32.47% to $135.0 million in 2024, then slumped by 57.78% to $57.0 million in 2025, then soared by 112.28% to $121.0 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $121.0 million in Q1 2026, $57.0 million in Q4 2025, and $22.1 million in Q3 2025.